Production (Stage)
Amylyx Pharmaceuticals, Inc.
AMLX
$5.31
-$0.05-0.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.27M | 87.37M | 196.49M | 298.76M | 398.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.27M | 87.37M | 196.49M | 298.76M | 398.00M |
| Cost of Revenue | 97.82M | 228.72M | 296.30M | 273.31M | 277.17M |
| Gross Profit | -99.09M | -141.35M | -99.82M | 25.45M | 120.83M |
| SG&A Expenses | 72.26M | 114.33M | 149.48M | 180.37M | 202.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 22.85M | 22.85M | 22.85M | 22.85M | -- |
| Total Operating Expenses | 229.13M | 402.10M | 468.63M | 476.52M | 479.28M |
| Operating Income | -230.40M | -314.73M | -272.14M | -177.76M | -81.28M |
| Income Before Tax | -219.49M | -302.14M | -257.48M | -162.36M | -65.66M |
| Income Tax Expenses | -635.00K | -393.00K | 1.99M | 3.51M | 5.44M |
| Earnings from Continuing Operations | -218.86 | -301.74 | -259.47 | -165.87 | -71.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -218.86M | -301.74M | -259.47M | -165.87M | -71.10M |
| EBIT | -230.40M | -314.73M | -272.14M | -177.76M | -81.28M |
| EBITDA | -229.66M | -313.83M | -271.10M | -176.64M | -80.08M |
| EPS Basic | -3.10 | -4.43 | -3.82 | -2.44 | -1.04 |
| Normalized Basic EPS | -2.03 | -2.87 | -2.46 | -1.58 | -0.69 |
| EPS Diluted | -3.11 | -4.44 | -3.82 | -2.45 | -1.07 |
| Normalized Diluted EPS | -2.03 | -2.87 | -2.46 | -1.59 | -0.71 |
| Average Basic Shares Outstanding | 290.41M | 272.56M | 271.39M | 270.71M | 269.92M |
| Average Diluted Shares Outstanding | 290.41M | 272.56M | 273.17M | 274.82M | 276.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |